GlobeNewswire Inc.··Macrogenics, Inc.MacroGenics Halts New Patient Enrollment in LINNET Trial Following FDA Clinical Hold
FDA places partial clinical hold on MacroGenics' LINNET trial due to serious adverse events including thrombocytopenia, myocarditis, and one death. New enrollment halted.
MGNXFDA clinical holdbispecific antibody